Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More
DIVIS LABORATORIES | NOVARTIS | DIVIS LABORATORIES/ NOVARTIS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 59.7 | 2,253.2 | 2.6% | View Chart |
P/BV | x | 13.8 | 29.9 | 46.0% | View Chart |
Dividend Yield | % | 0.4 | 1.5 | 30.1% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DIVIS LABORATORIES Mar-19 |
NOVARTIS Mar-19 |
DIVIS LABORATORIES/ NOVARTIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,639 | 980 | 167.3% | |
Low | Rs | 1,115 | 600 | 185.8% | |
Sales per share (Unadj.) | Rs | 186.3 | 198.7 | 93.8% | |
Earnings per share (Unadj.) | Rs | 51.0 | 21.0 | 243.0% | |
Cash flow per share (Unadj.) | Rs | 57.3 | 22.3 | 257.5% | |
Dividends per share (Unadj.) | Rs | 16.00 | 10.00 | 160.0% | |
Dividend yield (eoy) | % | 1.2 | 1.3 | 91.8% | |
Book value per share (Unadj.) | Rs | 261.8 | 307.5 | 85.1% | |
Shares outstanding (eoy) | m | 265.47 | 24.69 | 1,075.2% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 7.4 | 4.0 | 185.9% | |
Avg P/E ratio | x | 27.0 | 37.7 | 71.7% | |
P/CF ratio (eoy) | x | 24.0 | 35.5 | 67.7% | |
Price / Book Value ratio | x | 5.3 | 2.6 | 204.7% | |
Dividend payout | % | 31.4 | 47.7 | 65.8% | |
Avg Mkt Cap | Rs m | 365,592 | 19,508 | 1,874.1% | |
No. of employees | `000 | 11.8 | 0.6 | 2,039.1% | |
Total wages/salary | Rs m | 5,423 | 1,171 | 463.0% | |
Avg. sales/employee | Rs Th | 4,175.1 | 8,445.4 | 49.4% | |
Avg. wages/employee | Rs Th | 457.7 | 2,015.7 | 22.7% | |
Avg. net profit/employee | Rs Th | 1,141.8 | 891.0 | 128.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 49,463 | 4,907 | 1,008.0% | |
Other income | Rs m | 1,556 | 783 | 198.9% | |
Total revenues | Rs m | 51,019 | 5,689 | 896.7% | |
Gross profit | Rs m | 18,718 | 123 | 15,243.0% | |
Depreciation | Rs m | 1,689 | 32 | 5,311.3% | |
Interest | Rs m | 35 | 16 | 220.1% | |
Profit before tax | Rs m | 18,551 | 858 | 2,162.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 5,023 | 340 | 1,477.4% | |
Profit after tax | Rs m | 13,527 | 518 | 2,613.0% | |
Gross profit margin | % | 37.8 | 2.5 | 1,512.1% | |
Effective tax rate | % | 27.1 | 39.6 | 68.3% | |
Net profit margin | % | 27.3 | 10.6 | 259.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 46,501 | 8,055 | 577.3% | |
Current liabilities | Rs m | 8,468 | 1,850 | 457.7% | |
Net working cap to sales | % | 76.9 | 126.4 | 60.8% | |
Current ratio | x | 5.5 | 4.4 | 126.1% | |
Inventory Days | Days | 131 | 45 | 290.6% | |
Debtors Days | Days | 86 | 34 | 253.1% | |
Net fixed assets | Rs m | 25,797 | 150 | 17,220.8% | |
Share capital | Rs m | 531 | 123 | 430.2% | |
"Free" reserves | Rs m | 68,962 | 7,469 | 923.4% | |
Net worth | Rs m | 69,493 | 7,592 | 915.4% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 80,383 | 9,824 | 818.2% | |
Interest coverage | x | 531.0 | 54.9 | 966.5% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.5 | 123.2% | |
Return on assets | % | 16.9 | 5.4 | 310.6% | |
Return on equity | % | 19.5 | 6.8 | 285.5% | |
Return on capital | % | 26.7 | 11.5 | 232.4% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 24.6 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 12,187 | NA | - | |
Fx inflow | Rs m | 41,238 | 58 | 71,593.1% | |
Fx outflow | Rs m | 12,405 | 1,326 | 935.3% | |
Net fx | Rs m | 28,833 | -1,269 | -2,272.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 9,543 | -1,943 | -491.2% | |
From Investments | Rs m | -6,854 | 2,742 | -249.9% | |
From Financial Activity | Rs m | -2,459 | -298 | 824.7% | |
Net Cashflow | Rs m | 230 | 501 | 45.8% |
Indian Promoters | % | 52.0 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 75.0 | - | |
Indian inst/Mut Fund | % | 11.8 | 2.0 | 590.0% | |
FIIs | % | 19.0 | 1.6 | 1,187.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.2 | 21.5 | 80.0% | |
Shareholders | 31,796 | 41,647 | 76.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DIVIS LABORATORIES With: ALKEM LABORATORIES FRESENIUS KABI ONCO. TTK HEALTHCARE ALEMBIC PHARMA CADILA HEALTHCARE
Compare DIVIS LABORATORIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets rallied nearly 2% yesterday, boosted by realty and finance stocks. Benchmark indices registered sharp gains yesterday after a massive selloff in the past two days.
For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More